Overview

Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and tolerability of AEB071 in the treatment of active, moderate to severe ulcerative colitis in patients who have failed conventional therapy using mesalamine or steroids
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals